Personalizing IBD Management: Utilizing Precision Medicine and Innovative Therapies
Webinar/Online
Tuesday, August 12, 2025 at 6:00pm ET - 7:00pm ET
Add this event to your calendar
Info
Topic
The emergence of biologic and small-molecule therapies offers new opportunities for effective treatment of inflammatory bowel disease (IBD), yet the lack of predictive biomarkers and the diverse nature of treatment responses pose significant challenges. Education on precision medicine, integration of patient-reported outcomes, and a deep understanding of the latest therapeutic options are essential to optimize patient care. By enhancing knowledge and skills in these areas, healthcare professionals can better align treatment strategies with patient needs, improve clinical outcomes, and reduce overall healthcare costs associated with IBD. With the increasing global prevalence and complex nature of IBD, encompassing ulcerative colitis (UC) and Crohn’s disease (CD), the healthcare burden is substantial and growing. This targeted education is not only crucial for improving patient quality of life but also for advancing the field of IBD management.
Credits Offered
This event offers
1.0 CME credit
to attendees.
Accreditation Info:
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians..
Additional Information
TARGET AUDIENCE
This educational activity has been designed for gastroenterologists and other healthcare professionals who manage patients with IBD.
LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
- Define precision medicine and discuss its plausible application in clinical scenarios to optimize the care and treatment of patients with inflammatory bowel disease
- Integrate patient-reported outcomes into clinical practice to ensure shared-decision making and patient-centric care in UC and CD
- Describe the rationale for and clinical data supporting the mechanism of action, efficacy, and safety of approved biologic and small molecular drugs for the treatment of UC and CD
Speakers
Chief, Pediatric Gastroenterology & Hepatology
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Hospital
New York, New York
Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children's Hospital. She is also the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in over 340 peer reviewed journals including The New England Journal of Medicine, Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, Journal of Crohn’s and Colitis, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals. Mount Sinai Health System’s Marla C. Dubinsky, MD, and Laurie A. Keefer, PhD, are co-founders of Trellus Health, which has entered into an exclusive multi-year contract with Mount Sinai to commercialize a patent-pending GRITT-IBD™ resilience assessment and personalized integrated care pathways. Read about "The Science of Resilience Meets Technology" in the 2021 Mount Sinai Kravis Children's Hospital Pediatric Report. Dr. Dubinsky received the 2022 Sherman Prize National Recognizing for Excellence in Inflammatory Bowel Disease. Learn More Here. The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
Associate Professor, Division of Gastroenterology
Icahn School of Medicine at Mount Sinai Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Hospital New York, New York